Skip to main content
S&P 5007,706.03-0.75%DOW51,511.59-0.68%NASDAQ26,936.04-1.13%BTC$84,537.00-1.90%ETH$2,688.82-2.10%GOLD$4,322.10+0.09%OIL$92.69+0.58%
Smart Investors Daily
Bio-Rad Laboratories, Inc. logo

NYSE · BIO

Bio-Rad Laboratories, Inc.

Healthcare · Medical - Devices

$379.57

Down-$0.69 (-0.18%)

Updated Sep 23, 2026, 9:55 PM

SID Score

6.0/10

Composite research score

Smart Money

58/100

Neutral

Market cap
8.47B
P/E ratio
-12.51
Dividend yield
0.00%
52-week range
$236.73 – $396.23
Volume
374.68K
Avg. volume
214.04K

Price performance

BIO price history

1M range · 20 trading sessions · Daily adjusted prices

BIO closed at $379.57 after 20 trading sessions, down 2.76% for the selected period.

Last close
$379.57
Period change
-2.76%
Period low
$368.55
Period high
$390.34
Daily close
View OHLC price history
BIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 22, 2026$377.53$383.25$374.01$379.57374.68K
Sep 21, 2026$381.58$381.58$373.47$377.33311.47K
Sep 18, 2026$383.05$383.05$374.805$376.41324.35K
Sep 17, 2026$384.23$385.71$377.69$382.41204.96K
Sep 16, 2026$378.25$385.325$375.00$379.03262.41K
Sep 15, 2026$366.33$380.91$366.28$378.00519.13K
Sep 14, 2026$365.66$370.52$365.66$368.55292.99K
Sep 11, 2026$370.45$373.71$368.69$369.32344.83K
Sep 10, 2026$379.92$382.01$368.56$368.75334.38K
Sep 9, 2026$380.00$380.06$373.34$376.97177K
Sep 8, 2026$390.73$390.73$379.49$380.12138.84K
Sep 4, 2026$380.84$386.78$376.20$386.11112.95K
Sep 3, 2026$390.00$394.29$381.06$387.90148.03K
Sep 2, 2026$380.62$389.83$380.225$388.51285.33K
Sep 1, 2026$387.88$387.88$380.27$380.96256.11K
Aug 31, 2026$393.85$394.02$382.13$386.12301.42K
Aug 28, 2026$390.82$392.29$382.102$387.70206.97K
Aug 27, 2026$389.03$396.23$386.69$389.94245.88K
Aug 26, 2026$393.10$393.10$385.50$388.64221.66K
Aug 25, 2026$384.00$390.83$377.80$390.34295.72K

Latest BIO news

The latest Smart Investors Daily articles mentioning BIO.

Stock researchCompany · Overview

BIO research

Overview

Company profile and research snapshot.

Company profile

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$340.00
Implied upside
—
Analysts
—
BIO recent ratings
DateFirmRatingTarget
Aug 7, 2026RBC CapitalOutperform—
Aug 5, 2026Wells FargoEqual-Weight—
Aug 5, 2026RBC CapitalOutperform—
Aug 5, 2026CitigroupNeutral—
May 15, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 23, 2026

Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading

The microfluidics market presents significant opportunities in laboratory-on-a-chip research, miniaturized diagnostics, pharmaceutical R&D, and personalized medicine. Growth drivers include advancements in IoT integration, point-of-care diagnostics, and high-throughput screening, with North America leading the expansion. Microfluidics Market Microfluidics Market Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Microfluidics Market Report 2026" has been added to ResearchAndMarkets.com's offering. T

Yahoo · Feb 19, 2026

Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter and full-year results despite a challenging year marked by geopolitical uncertainty and continued pressure on academic research. The company delivered modest revenue growth and strong free cash […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By